  This study is a pharmacokinetic ( PK) and pharmacodynamics ( PD) approach using betahistine doses levels in unilateral vestibular neurectomized cats ( UVN) comparable to those used in humans for treating patients with Meni√®re 's disease. The aim is to investigate for the first time oral betahistine administration ( 0.2 and 2 mg/kg/day) with plasma concentrations of betahistine and its major metabolite 2-pyridylacetic acid ( 2-PAA) (